Sheldon Solomon, MD
Rheumatology · Voorhees, NJNPI 1699712810
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $202 of the $335 with a category attached, or 60.4%. 5 manufacturers reported payments, led by Johnson & Johnson at 47.7% of the total. That places this record below the midpoint for rheumatology clinicians in NJ, where the typical reported total is $2,436.
Across 13 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$160
- AbbVie$76
- Amgen$37
- Novartis$36
- GSK$25
Across 4 payments — averaging $9030.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$30K
- Pfizer$6K
What the payments were for
- Food & beverage$20260%
- Education$13340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 3 | $160 |
| AbbVie | 5 | $76 |
| Amgen | 1 | $37 |
| Novartis | 3 | $36 |
| GSK | 1 | $25 |
How this compares
$335 in reported general payments places this provider in the 15th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 18 | $185,458 |
| Humira(Cf) PenAdalimumab | 17 | $162,357 |
| Teriparatide | 24 | $70,056 |
| TymlosAbaloparatide | 18 | $45,695 |
| MethotrexateMethotrexate Sodium | 245 | $7,856 |
| Hydroxychloroquine Sulfate | 111 | $5,687 |
| Prednisone | 206 | $2,159 |
| Tramadol Hcl | 266 | $1,956 |
| Colchicine | 21 | $1,725 |
| Diclofenac Sodium | 13 | $1,303 |
| Potassium Chloride | 22 | $1,075 |
| Allopurinol | 81 | $976 |
| Gabapentin | 93 | $929 |
| Famotidine | 43 | $863 |
| Chlorthalidone | 40 | $406 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Voorhees
- Adrienne HollanderVoorhees$214K
- Joshua SundharVoorhees$137K
- James DwyerVoorhees$35K
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Edward AllegraRed Bank$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.